AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00720382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15% azelastine hydrochloride
Description: 1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
Study NCT00720382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
Study NCT01277159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. Control Nerve Block. IV Dexamethasone (4 mg).
Description: A. Control Nerve Block. IV Dexamethasone (4 mg).
Study NCT01277159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. Nerve Block with Dexamethasone (4 mg). IV saline.
Description: B. Nerve Block with Dexamethasone (4 mg). IV saline.
Study NCT01277159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
Description: C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
Study NCT01277159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
Description: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
Study NCT01277159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
Description: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
Study NCT00351403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: Rebetol 200 mg: applied as hard capsule
Study NCT00351403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Rebetol 200 mg: applied as hard capsule
Study NCT00351403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa 2b
Description: PegIntron (50/80/100/120/150 microgram): applied by injection
Study NCT00351403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2b
Description: PegIntron (50/80/100/120/150 microgram): applied by injection
Study NCT00822692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trim/ Sulfa DS
Description: bactrim DS (800/160) two tablets PO BID x 7 days
Study NCT00822692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo 2 pills PO BID x 7 days
Study NCT03888963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
Study NCT03888963 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: patients will be subjected to the same procedure like PRF group without giving PRF
Study NCT01711515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01711515 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT01711515 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo intracavitary brachytherapy
Study NCT01711515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01711515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04641598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Scratch
Description: An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch.
Study NCT04641598 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
Study NCT01431365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Group
Description: Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
Study NCT01431365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Sitting Group
Description: Participants will be required to sit passively for 10 minutes on a chair.
Study NCT04325932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urinary Kallikrein
Study NCT03323242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure
Description: The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
Study NCT03323242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Ultrasonic dissector
Description: The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
Study NCT04515381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch
Study NCT04515381 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Making measurements at the beginning of the research and 4 weeks
Study NCT04515381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Therapeutic Touch
Description: Sham Therapeutic Touch
Study NCT02171871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposed to a smoking environment
Description: Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
Study NCT05509075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: nutraceuticals
Description: antioxidants
Study NCT00781807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-module rehabilitation program
Description: The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support
Study NCT00676260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
Study NCT00676260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
Study NCT04578561 — intervention group
Intervention type: PROCEDURE
Intervention: Prophylactic mesh use
Description: After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
Study NCT01691976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oestrogen Patches
Study NCT01691976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHa
Description: Luteinising hormone releasing-hormone agonists (LHRHa)
Study NCT00576472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Please see detailed description for dosing information and study design.
Study NCT03150277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Description: 2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
Study NCT03150277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heavy resistance exercise
Description: 10 single repetitions of back half squats at 90% of 1 repetition maximum
Study NCT02175368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhese One F Upgrade
Study NCT00519662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-314
Description: Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1
Study NCT03832608 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is not intervention to be administered, only collection of data through various tests and questionnaires.
Study NCT01606033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
Study NCT01606033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire
Description: understanding of the implications of participating in a clinical trial
Study NCT03041363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin will be administered for 7 days 4 times daily.
Study NCT02499042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
Study NCT02499042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
Study NCT03668405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513
Description: Injection
Study NCT01818492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-0501
Study NCT04418986 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: opposite clear corneal incisions (OCCI)
Description: Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision.
Study NCT04418986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opposite clear corneal incisions (OCCI)
Description: Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision.
Study NCT01533454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
Study NCT01642017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
Study NCT03974295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaginal unprotected intercourse
Description: Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
Study NCT02940483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: 5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
Study NCT03841136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
Study NCT00659503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus Placebo
Study NCT00659503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00257660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 500 units
Study NCT00257660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 units
Study NCT05303688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)
Description: The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
Study NCT03908723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Description: Intravitreal Aflibercept with PRP to the peripheral vascular lesions
Study NCT05303688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steril Salin (control)
Description: 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
Study NCT02901652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive respiratory support devices
Study NCT04627233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ezrin Peptide 1 (HEP1)
Description: HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days
Study NCT02323152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
Study NCT02323152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
Study NCT01869660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
Study NCT03683888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthSnap
Description: HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
Study NCT03683888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary counseling
Description: Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
Study NCT04329494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given via PIPAC
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given via PIPAC
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04329494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Chemotherapy
Description: Undergo PIPAC
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given via PIPAC
Study NCT04329494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given via PIPAC
Study NCT04329494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04329494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02437084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Study subjects will receive atorvastatin 40 mg for 10 weeks.
Study NCT03108508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod1
Description: 60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
Study NCT03108508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod2
Description: 1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
Study NCT03108508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prod3
Description: 120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
Study NCT03681613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX program combined with a CNS-focused protocol
Description: The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training.
Study NCT03681613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX program
Description: The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
Study NCT02706379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local cerebral oxygen saturation
Description: take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
Study NCT03693547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone injection
Description: utidelone monotherapy in patients with advanced NSCLC by utidelone
Study NCT01888419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipotransplantation
Description: Lipotransplantation in general anaesthesia to the mastectomy site
Study NCT02613169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
Study NCT03324919 — intervention group
Intervention type: BEHAVIORAL
Intervention: HRQL
Description: Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
Study NCT04048226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine +Ketamine
Description: The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
Study NCT01634295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/40mg
Description: * Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Study NCT00884832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
Study NCT00884832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
Study NCT04370379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302 (the first dose level)
Description: q4week (3 injections) followed by PRN dosing
Study NCT04370379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI302 (the second dose level)
Description: q4week (3 injections) followed by PRN dosing